Drug Trial Radar · NCT07672405
Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 9, 2026
Primary completion
May 28, 2027
Study completion Jun 24, 2028
Sponsor
- Lead sponsor
- Global Alliance for TB Drug DevelopmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional trial is to evaluate the safety and efficacy of the loading dose regimen 200/100SPaL-4/13 weeks, and the 100SPaL -17 weeks regimen in adults with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. Participants (18-65 years) will be randomised 1:1, stratified by country and disease severity, to receive either : 1. a sorfequiline loading-dose regimen (200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks) plus pretomanid 200 mg and linezolid 600 mg daily, or 2. sorfequiline 100 mg daily for 17 weeks plus pretomanid 200 mg and linezolid 600 mg daily. Study treatment is administered orally once daily with food. The primary objective is to assess safety through 17 weeks of treatment, including treatment-emergent adverse events, ECG findings, vital signs, laboratory assessments, visual acuity, and peripheral neuropathy. Secondary objectives include assessments of efficacy (time to stable sputum culture conversion; favorable outcome and treatment failure/relapse at 26 and 52 weeks after end of treatment) and pharmacokinetics of trial drugs, with exploratory analyses including predictors of culture conversion, exposure-response relationships, and quality of life.
Conditions
- Tuberculosis, Pulmonary
Interventions
sorfequilineDrug
Two sorfequiline 100mg tablets taken once daily for 4 weeks then one sorfequiline taken once daily for 13 weeks OR one sorfequiline 100mg tablet taken once daily for 17 weeks (with one 100mg sorfequiline placebo tablet for the first 4 weeks)
PretomanidDrug
one 200mg tablet taken once daily for 17 weeks
LinezolidDrug
one 600mg tablet taken once daily for 17 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and characterization of treatment-emergent adverse events (TEAEs)Time frame: Through 17 weeks of treatment
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Synergy Biomed Research Institute
East London, South Africa · Not yet recruiting
Durban International Clinical Research Site
Wentworth, Durban, South Africa · Recruiting
Isango Lethemba TB Research Unit
Port Elizabeth, Eastern Cape, South Africa · Recruiting
Setshaba Research Centre
Soshanguve, Gauteng, South Africa · Recruiting
University of Capetown Lung Institute
Cape Town, Mowbray, South Africa · Recruiting
The Aurum Institute, Rustenburg
Rustenburg, North West, South Africa · Recruiting
Madiberg Centre for Research
Brits, North West Provinvce, South Africa · Recruiting
Perinatal HIV Research Unit, Tshepong Hospital
Klerksdorp, Northwest Province, South Africa · Not yet recruiting
INUKA Africa
Dar es Salaam, Tanzania · Not yet recruiting
NIMR-Mbeya
Mbeya, Tanzania · Not yet recruiting
Kilimanjaro Clinical Research Institute(KCRI)
Moshi, Tanzania · Not yet recruiting
NIMRI-Mwanza
Mwanza, Tanzania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.